Conclusions: Both agents given together outperformed either separately. Highest TGFβ doses and most frequent dose schedule were most effective. Activity was associated with a significant increase [45%] in Foxp3 expression by colonic lamina propria CD4+ CD25+ T-cells. Activity was also demonstrated in dextran sulphate sodium-induced colitis. The data support development of the combination product as a novel, targeted immune based therapy for treatment for IBD.
Introduction
Conventional therapies for inflammatory bowel disease [IBD] , including Crohn's disease [CD] and ulcerative colitis [UC] , fall into three groups: salicylates, immunosuppressants, and antibiotics. Although these are effective in treating active disease, remissions are often short-lived and associated with significant side effects. Despite therapy, 80% and 45% of CD and UC patients [respectively] require surgery.
Regulatory T-cells [Treg] and mucosal dendritic cells [DC] help maintain gut immune homeostasis and represent attractive therapeutic targets. 13, 14, 15, 16, 17 Adoptively transferred CD4+ CD25+ Foxp3+ TGFβ-dependent Tregs prophylactically and therapeutically limit IBD via direct suppression of T-effector priming activity and innate effector function. 18, 19, 20 Separately, mucosal DCs produce retinoic acid, an essential cofactor in TGFβ-dependent Treg generation in the gut. 16, 17 This retinoic acid requirement was linked to induction of Foxp3 expression in T cells. 21 Thus, these molecules represent potential therapeutic agents to treat IBD by activation and expansion of gut Tregs.
However, acid-induced hydrolysis and enzymatic degradation often prevent effective oral delivery of bioactive macromolecules, such as TGFβ. 22, 23 Encapsulation of labile biologicals into biodegradable polymer-based microspheres provides protection from stomach acids and proteases, allowing safe passage into the lumen of the gastrointestinal [GI] tract for uptake. 24, 25 Although the use of polymeric particles for oral drug delivery to the inflamed colon is not a new concept, 26 the utility of this technology in delivery of labile proteinbased therapeutics to gut tissues is yet to be fully determined. Phase inversion nano-encapsulation [PIN ® ] utilizes a non-mechanical encapsulation approach that preserves the structural integrity and biological activity of macromolecules, provides extended shelf life at room temperature [years] and allows effective delivery of protein therapeutics to the intestinal immune structures. 28, 29 In the present studies, we investigated whether oral administration of TGFβ-and ATRA-loaded PIN ® microspheres could ameliorate disease in murine models of IBD.
Methods

Preparation and characterization of ATRA-and
TGFβ-loaded microspheres 2.1.1. Microsphere preparation ATRA was encapsulated into poly [lactic-co-glycolic] acid microspheres [1 mg of ATRA per gram of particles] using a modification of the solvent evaporation technique. 27 Briefly, 5.0 mg of ATRA [Sigma-Aldrich] was dissolved in 20 ml dichloromethane [DCM] to produce a 250 mg/ml solution in an amber vial; 8 ml of this solution was added to 1000 mg of 503H polymer [Resomer] dissolved in 32 ml DCM to produce the oil phase; 20 μl of Span 80 was also pipetted into this solution. To prepare the water phase, 600 ml of 1% 25K polyvinyl alcohol [PVA] was added to a glass beaker placed on ice within a stainless steel container. The water phase was then set under a Silverson mixer at a shear rate of 4000 rpm for 75 min as the oil phase was added via a glass pipette. The emulsion was then transferred to the overhead mixer with an additional litre of double-distilled water and spun for 225 min. The microspheres were washed, centrifuged, and lyophilized for 48 h.
TGFβ was encapsulated into polylactic acid [PLA] microspheres [0.285 mg TGFβ per gram of particles] using PIN ® as described previously. 28 
In vitro drug release
Human recombinant TGFβ [Peprotech, Rocky Hill, NJ] was encapsulated into microspheres and release tested using an in vitro release assay described previously. 29 Briefly, 10 mg of TGFβ PIN ® particles were suspended in 1.0 ml release buffer and 0.2 ml transferred to the wells of a 96-well plate in triplicate. 
Stability studies
TGFβ particles were stored at 4 or -20 o C, and samples removed at selected time points. For each time point, an overnight release assay was performed as above. TGFβ concentration and bioactivity values in supernatants were then compared with those observed for the same samples prior to storage [unstored] . Final values for specific activity were expressed as % recovered bioactivity divided by % recovered protein.
TGFβ biological activity was tested using the TGFβ sensitive mouse lymphoblasT-cell line HT-2. Cells were plated at 1. [Germantown, NY] . The mice were kept under standard laboratory conditions with free access to food and water. They were allowed to adapt for 1 week before starting the study. The care and use of laboratory animals was in accordance with a University at Buffalo IACUC-approved animal use protocol. 
Isolation of CD4+ CD25-T-cells
Isolation of lymphocytes from lamina propria
Colonic lamina propria [LP] lymphocyte populations were isolated by enzymatic digestion of minced colonic sections followed by purification on lympholyte as described. 30 The CD4+ CD25+ T-cells were then analysed for Foxp3 expression by flow cytometry. 31 
Histology
Ascending, transverse, and descending colon from treated and control mice were fixed in 10% formalin, embedded in paraffin, sectioned [5 μm] and stained with haematoxylin and eosin [H & E] . Five randomly-selected sections from each mouse were scored for disease severity using the scoring method outlined in Table 2 
Dextran sodium sulphate-induced colitis
Animals
Mice 6 8-weeks old (C57Black6 mice [males: n = 6; females: n = 6; 12 per group]) were purchased from Harlan Nossan, San Pietro al Natisone, Udine, Italy, and housed in a vivarium under pathogen-free conditions at the Department of Biomedical Sciences in the School of Medicine at the University of Catania [Catania, Italy] . The mice were kept under standard laboratory conditions with free access to food and water. They were allowed to adapt for 1 week before starting the study. The care and use of laboratory animals was in accordance with a University of Catania IACUC-approved animal use protocol.
Induction of colitis and treatment
Colitis was induced with 3% dextran sodium sulphate [50 kDa; Sigma-Aldrich] in drinking water for 4 days. The first treatment was given 24 h before induction of colitis [Day -1] and continued every other day for 6 days.
Disease score, SAA levels and histology
Disease score, SAA levels and histological analysis were performed as above.
Statistical analysis
Significance [p ≤ 0.05] between experimental and control groups was determined using Student's t-test analysis. In experiments with multiple groups, homogeneity of inter-group variance was analysed by ANOVA.
Results
TGFβ is released from PIN ® microspheres over 4 days
A number of technologies encapsulate small molecules such as ATRA, achieving slow release. 27, 32 The gentle encapsulation of labile proteins, protecting them from degradation and retaining bioactivity and shelf stability, has been more elusive. Thus, the present studies focus on PIN ® encapsulated TGFβ. The 4-day release profiles for human TGFβ from PIN ® particles is shown in Figure 1A . These data demonstrate that an initial burst was followed by sustained cytokine release for at least 4 days. To determine whether the released TGFβ was active, we evaluated the 15-min time point samples for bioactivity. In this assay, the activity of the released protein was expressed as the concentration equivalent of unencapsulated TGFβ inducing that same amount of cell proliferation. Comparison of TGFβ concentrations as determined by bioassay versus ELISA revealed a high correlation [r 2 = 0.823] between the two assays, demonstrating that the activity of the encapsulated cytokine was fully preserved [ Figure 1B ]. 3.3. TGFβ-and ATRA-loaded PIN ® microspheres have optimal therapeutic effects on IBD when given in combination
We first sought to determine if either ATRA-or TGFβ-loaded PIN ® microspheres alone could ameliorate disease as effectively as the two in combination. Mice with established disease were fed with blank microspheres [control], ATRA-loaded microspheres alone, TGFβ-loaded microspheres alone, or with the combination. Treatment was three times a week for 2 weeks. Mice were sacrificed 4 days after last treatment for analysis of colons and sera.
In contrast to single-agent treatment groups, differences between control and TGFβ/ATRA treatment groups, in terms of percent body weight change [ Figure 3 panel A], changes in colon weight-to-length ratio [ Figure 3 panel B] and reduced SAA levels [ Figure 3 panel C] were significant. In terms of histological scoring, the combination group performed significantly better than the control or either agent alone [ Figure 3 panel D]. Whereas ATRA or TGFβ alone appeared to have modest effects overall, these were not statistically significant in most cases, suggesting that combined administration of TGFβ and ATRA is essential to optimal amelioration of established disease.
Effect of TGFβ or ATRA dose on therapeutic efficacy
In the next set of experiments, using the same CD4+ CD25-T-cell transfer model of IBD, dose-response analysis was first performed for TGFβ. Mice with established disease were treated orally with a constant dose of ATRA [ Figure 4 panel C] were significant at all dose levels. However, by all three measures, the 10-μg TGFβ dose appeared most effective. Next, keeping the TGFβ dose at10 μg, dose-response analysis was performed for ATRA [ Figure 5 ]. All doses of ATRA, except the highest dose tested, appeared to slow weight loss [ Figure 5 , panel A] although the 10-and 20-μg doses seemed most effective. In terms of colon weight-to-length ratio [ Figure 5 , panel B], an apparent dose response was observed except at the 40-μg dose, which was no more effective than the 20-µg dose. All doses of ATRA significantly reduced SAA levels [ Figure 5 panel C], with the exception of the 40-μg dose. Differences between treatment groups were not generally significant. These observations suggest that in the context of 10 μg TGFβ1, 20 μg ATRA is optimal in this model.
Effect of dose schedule on TGFβ/ATRA therapeutic activity
Having established effective doses for TGFβ/ATRA, the next parameter to be established in this model was the optimal treatment schedule. The same CD4+ CD25-T-cell transfer method was used to induce IBD in SCID mice. When the mice became symptomatic for IBD, they were separated into groups as follows: Group 1: untreated controls; performed best. A dosing schedule consisting of three treatments per week was also found to be superior by colon weight-to-length ratio [ Figure 6 panel B] and reduced SAA levels [ Figure 6 panel C].
Treatment of established IBD disease with TGFβ/ ATRA-loaded microspheres
To more fully test the optimised ability of oral TGFβ/ATRA-loaded microspheres to ameliorate established IBD, a larger cohort study with frequent monitoring of five independent parameters was undertaken. TGFβ/ATRA-loaded [10 and 20 ug] or blank microspheres [ACT; adoptive cell transfer] were administered orally three times per week for 2 weeks, and mice were monitored for overall disease score [ Table 1 ] and weight loss three times a week. At the end of 2 weeks, animals were sacrificed and SAA levels, colon weight-tolength ratios and colon histology scores determined.
Treatment reversed disease rapidly as overall disease score declined within 4 days of treatment and remained low, whereas it increased from an average of 8 or 9 to over 12 in control [ACT alone] mice during the 14-day treatment interval [ Figure 7 panel A].
Similarly, whereas the mice in the control group progressively lost weight [average of 17%] during this period, the weight remained stable in the treated group [ Figure 7 panel B].
Mice were sacrificed on day 18 after first treatment [4 days after last treatment] and levels of SAA determined [ Figure 7 panel C]. Age-matched naive SCID mice [no adoptive cell transfer] were used to establish the baseline SAA levels [~ 14 μg/ml in naive SCID]. These observations confirmed the above pattern of reduced disease score and suggested an even more dramatic reversal of disease. In control mice [ACT; fed blank particles alone] SAA levels increased over 50-fold to an average of ~ 850 μg/ml. In contrast, TGFβ/ATRA treatment reduced SAA levels to ~ 39 μg/ml. Differences between naive and control, and naive and TGFβ/ATRA-treated, groups were significant. Importantly, the difference between the control and the TGFβ/ATRA group was also significant. The colons of sacrificed mice were also analysed for colon weight-to-length ratio [ Figure 7 panel D]. Colon weight-to-length ratio increased 2.7-fold in the control group in contrast to only a 1.6-fold increase in treated mice when compared with naive SCID mice. Treatment resulted in a 45% decline in colon thickening. Table 2 ] for disease severity. A 22-fold increase in disease score was observed in control mice compared with naive SCID mice, whereas the severity of disease was increased only by 6-fold in the treated group [ Figure 7 panel E]. The difference between naive and control was highly significant. More importantly, the difference between control and TGFβ/ATRAtreated mice was highly significant whereas naive and TGFβ/ATRAtreated mice were not significantly different.
Efficacy and toxicity of long-term TGFβ/ATRA microsphere therapy
IBD was established in SCID mice using the same adoptive cell transfer model as before. Mice were considered to have IBD when they attained a disease score of 9 or above. At that time, mice were entered into control or treatment groups and treatments initiated. Treatments were administered for 8 weeks and consisted of three treatments each week of encapsulated TGFβ [10 μg] and ATRA [20 μg]. Mice were sacrificed if they developed rectal prolapse, their disease score exceeded a total of 17, or if they attained a score of 5 in any scoring category. The study was concluded and all remaining mice were sacrificed at 8 weeks [after 24 treatments].
The colon weight-to-length ratio of the control [ACT alone] mice was similar to that seen in control animals in earlier experiments regardless of the length of time with IBD [ Figure 8, panel A] . Similarly, the mice receiving TGFβ/ATRA treatment for an extended 8-week period maintained the same colon weight-to-length ratio that is seen in mice that were treated for only 2 weeks. Lungs from mice receiving TGFβ/ATRA treatment for 8 weeks showed no statistically significant [p = 0.84] difference in the lungto-body weight ratio compared with untreated mice with IBD [data not shown], arguing against any fibrosis or systemic effect and for only therapeutic action.
Increased Foxp3+ expression in colonic lamina propria CD4+ CD25+ T-cells from treated animals
Oral treatment with TGFβ/ATRA particles induced a 45% increase [versus animals given blank particles] in Foxp3 mean florescence intensity [MFI] in CD4+ CD25+ colonic lamina propria regulatory T-cells [ Figure 9 ]. This is consistent with the current paradigm that TGFβ and retinoic acid synergise in inducing T-regulatory cell phenotype and function and provides support for the hypothesis that oral administration of sustained-release TGFβ and ATRA ameliorates established disease by shifting the CD4+ effector/Treg balance in favour of the regulatory phenotype in the GI tract.
TGFβ/ATRA-loaded microspheres attenuate DSS-induced colitis
To more broadly test the ability of oral TGFβ/ATRA-loaded microspheres to ameliorate IBD, a second model, the DSS-induced colitis model, was employed. TGFβ/ATRA-loaded [10 and 20 µg, respectively] or blank microspheres [control] were fed [gavage] to mice [n = 12 per group] 24 h before induction of colitis [Day -1] and then every other day for 6 days. As a positive control group, eight additional mice were treated orally with sulphasalazine at the dose of 50 mg/kg daily for 7 consecutive days starting from Day 2. Mice were monitored daily for overall disease score and weight loss. At the end of 7 days, animals were sacrificed and SAA levels, colon weight-to-length ratios, and histology scores determined.
TGFβ/ATRA treatment attenuated disease as evidenced by significantly [p < 0.001] reduced cumulative disease score compared with either untreated animals, or mice fed blank particles [control; Figure 10 , panel A] however, neither sulphasalazine nor TGFβ/ATRA treatment was able to reduce weight loss in this model [ Figure 10 , panel B].
Mice were sacrificed 7 days after first treatment and levels of SAA determined [ Figure 10 , panel C]. Naive C57Black6 mice [no disease] were used to establish baseline SAA levels [~ 20 μg/ml]. These observations confirmed the above pattern of reduced disease score. In control groups [mice left untreated or fed blank particles] SAA levels increased over 10-fold to an average of ~ 350 μg/ml. In contrast, TGFβ/ATRA treatment reduced SAA levels to less than 300 μg/ml. Differences between no treatment and suphasalazineand TGFβ/ATRA-treated groups were significant. Importantly, the difference between the control and the TGFβ/ATRA group was also highly significant [p < 0.001]. The colons of sacrificed mice were also analysed for colon weight-to-length ratio [ Figure 10 panel D].
Colon weight-to-length ratio increased to almost 40 mg/cm in the control groups in contrast to only 35 mg/cm in sulphasalazine-and TGFβ/ATRA-treated mice. This difference was also significant [p < 0.01]. Next, ascending, transverse, and descending colon from naive C57Black6 [no disease], untreated, TGFβ/ATRA-treated, and control [fed blank particles] mice were fixed in 10% formalin, embedded in paraffin, sectioned [5 μm] and stained with H & E. Five randomly-selected sections from each mouse were scored [ Table 2 ] for disease severity. Cumulative histological score was nearly 12 in untreated and control mice, but was reduced to less than 10 in the treated groups [ Figure 10 panel E]. The differences were highly significant [p < 0.001]. Importantly, TGFβ/ATRA performed as well as the positive control drug sulphasalazine in this model.
Discussion
We have shown that TGFβ-loaded PIN ® microspheres provide sustained release of bioactive protein in vitro for at least 4 days and that the formulation is stable at -20 and 4 o C for at least 52 weeks. The combination of TGFβ and ATRA diminished the symptoms of established IBD in both CD4+ CD25-T-cell transfer and DSS-induced colitis models as evidenced by significant changes in multiple disease markers. Higher and more frequent doses were more effective and both were required to achieve maximal disease amelioration, which was associated with enhanced Foxp3 expression in lamina propria CD4+ CD25+ T-cells. TGFβ is an acid labile protein and, working under the assumption that encapsulation would improve efficacy and enhance stability and storage options, we chose to focus our initial studies on this macromolecule.
The systemic or local administration of TGFβ protects in several autoimmune disease models 33, 34, 37, 38 but requires microgram doses. Gene therapy approaches have economically produced effective amounts 33, 35 but high systemic levels raise serious safety concerns including pulmonary fibrosis and scleroderma, 39 ,40,41,42,43 chronic graft vs host disease 44 and glomerulonephropathies. 45 Thus, fibrosis was an expected treatment side effect. However, surprisingly, our results suggested that any fibrosis was limited to that caused by disease at the time of treatment initiation. This is evidenced by our observation that long-term oral treatment with TGFβ/ATRA combination did not lead to an increased colon weight-to-length ratio, as would be expected in the case of treatment-induced fibrosis. Instead, results indicated that long-term treatment with TGFβ/ATRA slowed disease progression, prolonged survival, and did not increase intestinal fibrosis. Additionally, we found that long-term oral treatment with TGFβ/ATRA did not induce lung fibrosis as evidenced by no increase in lung-to-body weight ratio compared with untreated mice with IBD [data not shown].
Oral delivery of low doses of TGFβ targeted to the GI tract could significantly improve the efficacy of TGFβ treatment in IBD patients while avoiding the potential problems associated with gene therapy and toxicities associated with systemic TGFβ administration. In this regard, we conducted a bioavailability and pharmacokinetic study of TGFβ and ATRA following a single oral administration of PIN . Area under the curve [AUC] was 10 ng-hr/ml. These observations generally agree with the literature. 46 In contrast, for the oral TGFβ encapsulated group [100 mg/kg], very little TGFβ [~ 500 pg/ ml] was observed in serum and quickly declined to undetectable levels [C max ~ 30 min]. For ATRA, serum levels [~ 3000 ng/ml] peaked at 5 min after IV injection of soluble drug [1.6 mg/kg] and declined rapidly over the first hour [t 1/2 = 34 min]. AUC was 3.5 ug-hr/ml. These observations also generally agree with the literature. 47 The oral encapsulated ATRA group [18 remains that oral TGFβ could be responsible for the development of intestinal fibrosis during treatment for chronic colitis. In contrast to TGFβ, ATRA is a small molecule with significant oral bioavailability and wider storage options. 48 The ability of nanoparticulate ATRA to suppress Th17 cells and induce regulatory T-cells in vitro has already been reported. 49 In addition, the efficacy of ATRA alone in IBD models is well established. By using mice that overproduce tumour necrosis factor [TNF] and develop chronic ileitis [TNFΔARE mice], Collins and colleagues 50 showed that twice-weekly ATRA injections (300 μg given intraperitoneally [IP]) significantly attenuated established disease by increasing the number and function of CD103+ DCs and regulatory T-cells while reducing Th17 cells. Bai and colleagues 51 showed that IP treatments of mice with ATRA ameliorated disease in the TNBS colitis model as judged by improved body weight and colon inflammation. Hong and colleagues 52 showed similar efficacy for ATRA in the mouse model of DSS-induced colitis. However, studies by Sanders 53 and colleagues suggested complexity in human tissue. Macrophages from the intestinal mucosa of Crohn's disease patients showed an increased capacity to generate ATRA, where it increased pro-inflammatory phenotypes. Initial reports suggested that ATRA might serve as a trigger for IBD, especially UC. 54, 55 However, a series of recent clinical studies found no association between ATRA use and IBD, and even indicated decreased risk. 56, 57 ATRA is used to treat severe cystic acne [also known as nodular acne] that has not responded to other treatment 58 as well as acute promyelocytic leukemia [APML] . 59, 60, 61 Despite its effectiveness, it has been associated with depression, suicidality, and teratogenicity. 59 It has been suggested that this systemic toxicity could be avoided by targeting administration to the desired tissue site. Examples of this approach include immune-targeting of liposomal retinoids 62 or retinoid aerosolisation. 63 One study sought to suppress epithelial carcinogenesis by delivering ATRA micro-particles via a subcutaneous injection. The slow release of ATRA from these particles resulted in a therapeutically significant release of ATRA without significant toxicity. 64 From those studies it appears that targeting ATRA to the inflamed bowel in IBD should result in a significant reduction in the amount of drug needed while decreasing the possibility of side effects. Thus, the oral delivery of encapsulated ATRA should have a therapeutic advantage over parenteral or intravenously administered drug.
We found that ATRA-or TGFβ-loaded microspheres given alone had only modest effects that were not statistically significant in most cases. Both were required for broadly significant benefit, which was associated with enhanced Foxp3 expression by the colonic lamina propria CD4+ CD25+ T-cells. We did not perform functional assays, but these findings are consistent with numerous reports supporting the requirement for ATRA in TGFβ-driven development of regulatory T-cells 17, 65, 66, 67 and suggesting that ATRA is needed as a co-factor in TGFβ-based IBD therapy. In the presence of ATRA and TGFβ, antigen-activated naive T-cells become regulatory T-cells 16, 17, 66, 68 while in the presence of IL-6, TGFβ promotes Th-17 T-cells. 67 Mechanistically, ATRA increases FoxP3 expression by Treg cells and inhibits the development of Th17 cells by enhancing TGFβ-driven Smad3 signalling and inhibiting IL-6 and IL-23 receptor expression. 69 This also suggests that another advantage to the combined product may be that ATRA tends to reduce the side effects of TGFβ.
Encapsulation of labile biologicals into biodegradable polymers provides protection from the acidic environment and the proteases of the stomach and allows safe passage through the lumen of the GI tract for uptake. 70 Until recently, this technology primarily targeted small-molecule drugs and peptides because larger bioactive macromolecules are generally more highly sensitive to organic solvents and mechanical agitation techniques that are used during encapsulation. PIN ® technology has now made it possible to encapsulate biologically active macromolecules into biodegradable polymer microspheres while preserving biological activity. We have not strictly demonstrated targeted delivery of TGFβ/ΑΤRΑ to the gut in these series of studies, but our previous work showed that orally administered protein-loaded PIN ® microspheres are efficiently taken up in Peyer's patches and mesenteric lymph nodes. 71 Three different strategies to locally deliver biopharmaceutical drugs to the gut using oral administration of nanoparticles have recently been compared. 
